Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Cynapsus Therapeutics Inc

+ Add to Watchlist

CYNAF:US

0.9680 USD 0.0342 3.66%

As of 20:10:04 ET on 03/31/2015.

Snapshot for Cynapsus Therapeutics Inc (CYNAF)

Open: 0.9452 Day's Range: 0.9000 - 0.9700 Volume: 188,745
Previous Close: 0.9338 52wk Range: 0.4000 - 1.2200 1-Yr Rtn: +21.00%

Stock Chart for CYNAF

No chart data available.
  • CYNAF:US 0.9550
  • 1D
  • 1M
  • 1Y
0.9338
Interactive CYNAF Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CYNAF

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (CAD) (ttm) -
Est. EPS (CAD) (12/2015) -
Est. PEG Ratio -
Market Cap (M USD) 85.44
Shares Outstanding (M) 88.27
30 Day Average Volume 173,804
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CYNAF

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for CYNAF

Cynapsus Therapeutics, Inc. researches and develops pharmaceuticals. The Company researches treatments for Parkinson's disease, neuropathic pain associated with multiple sclerosis and cancer, and nausea and vomiting and appetite stimulation.

Anthony J GiovinazzoPresident/CEOAndrew Michael WilliamsCFO/COO
Thierry BilbaultExec VP:CMC/Chief Scientific Ofcr
More Company Profile & Key Executives for CYNAF

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil